Loading
institutionsInstitution
Ruijin Hospital, Shanghai Jiao Tong University
The hospital where all-trans retinoic acid and arsenic cured acute promyelocytic leukaemia, and still China's leading haematology centre.
Also called: Ruijin Hospital瑞金医院Shanghai Institute of Hematology
Overview
Ruijin Hospital dates to 1907 and is home to the Shanghai Institute of Hematology, where Zhen-Yi Wang and Zhu Chen established differentiation therapy of acute promyelocytic leukaemia with all-trans retinoic acid and then arsenic trioxide, turning a lethal leukaemia into one of the most curable. The institute remains a global reference for APL, AML genomics and lymphoma, and hosts national CAR-T and haematopoietic transplant programmes. Ruijin is also a major centre for gastric cancer surgery, pancreatic surgery, endocrine tumours and burns, and runs one of Shanghai's proton therapy projects.
Location
Shanghai, CN
Type
hospital · Shanghai Jiao Tong University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#213 · 28 points (0 Newsweek + 0 NCI + 28 from 14 linked objects) · ranking
- Shanghai Institute of Hematology
- APL differentiation therapy
- Lymphoma
- Gastric and pancreatic surgery
- Proton therapy
Saijuan Chen
Professor; Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Acute promyelocytic leukaemiaLeukaemia genomicsDifferentiation therapy
Saijuan Chen helped turn acute promyelocytic leukaemia from a leukaemia that often killed within weeks into one of the most curable, by showing how retinoic acid and arsenic act and combining them.
Zhu Chen
Professor, Shanghai Institute of Hematology, Ruijin Hospital; former Minister of Health of China (2007 to 2013)
Acute promyelocytic leukaemiaMolecular haematologyHealth policy
Zhu Chen, a leukaemia scientist who became China's health minister, co-developed the retinoic acid plus arsenic treatment that cures most acute promyelocytic leukaemia and then reformed the health system that pays for it.
Similar pages
- TrialAPL0406
Shares Tretinoin (all-trans retinoic acid, ATRA), Arsenic trioxide, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- TargetRetinoic acid receptor alpha (RARA)
Shares Tretinoin (all-trans retinoic acid, ATRA), Arsenic trioxide, Acute myeloid leukaemia.
- InstitutionNational University Hospital / National University Cancer Institute, Singapore
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), CAR-T cell therapy, Acute myeloid leukaemia, Gastric & gastro-oesophageal junction cancer.
- TrialRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Shares Tretinoin (all-trans retinoic acid, ATRA), Pancreatic ductal adenocarcinoma.
- TargetPML
Shares Tretinoin (all-trans retinoic acid, ATRA), Arsenic trioxide.
- InstitutionMayo Clinic Comprehensive Cancer Center in Arizona
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, CAR-T cell therapy, Pancreatic ductal adenocarcinoma.
- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, Acute myeloid leukaemia.
- CompanyProTom International
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy.
cancers
fronts
technologies
drugs
ApprovedInorganic arsenical (differentiation agent)
Arsenic trioxide · Trisenox
ApprovedOral retinoid (differentiation agent)
Tretinoin (all-trans retinoic acid, ATRA) · Vesanoid